Scorpion Therapeutics, Inc.
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Scorpion Therapeutics, Inc.
Axel Hoos helped create the field of immuno-oncology and now has his sights on proving the worth of Scorpion Therapeutics’ precision oncology platform. The executive spoke with In Vivo about company culture, the Scorpion strategy and resilience in the face of resistance.
The French firm has followed up its recent acquisition of Swiss lung cancer specialist Vertical Bio by signing a pact with Vernalis.
Plus deals involving Kelun Biotech, Pierre Fabre/Vertical, Novo Nordisk/Broad Institute, ABL Bio/Synaffix, Kriya/Tramontane, Palisade/Giiant and more.
The oncology start-up signed a co-development and commercialization agreement with the French pharmaceutical company for two next-generation EGFR inhibitors.
- Drug Discovery Tools
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.